Sequence Bio, a Newfoundland and Labrador-based biotechnology company, announced that president and chief executive officer Chris Gardner has stepped down from his position and from the company’s Board. Gardner will remain a strategic advisor to the company. Lynn Healey has been appointed interim CEO from her previous position as Sequence Bio’s Chief Operating and Financial Officer.
“My fellow board members and I want to thank Chris for his leadership, commitment, and contributions to Sequence Bio. He is an outstanding operator and was instrumental in building the company into one of the country’s top employers, and an emerging drug discovery partner to world-leading therapeutics companies. We look forward to seeing what Chris will accomplish next,” said Mark Dobbin, Chair of the Board.
He continued, “While a search for a permanent CEO is underway, we are pleased with the appointment of Lynn Healey as interim CEO and have every confidence in her proven ability to move the company forward during this brief transition period.”
Lynn Healey joined Sequence Bio in April 2021 with over 25 years of strategic leadership experience. Previously, Lynn was the Chief Investment Officer of the Teachers’ Pension Plan Corporation and a Partner at Ernst & Young (EY).
Sequence Bio is a commercial-stage biotechnology company based in Newfoundland and Labrador, Canada. The company’s platform leverages Newfoundland’s founder effect to power discovery cohorts for novel target identification across numerous disease indications. Sequence Bio collaborates with the people of Newfoundland and Labrador, and partners with leading pharma and biotech to help accelerate the development of new medicines for global unmet medical needs.